Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: In vivo hepatogenic capacity and therapeutic potential of stem cells from human exfoliated deciduous teeth in liver fibrosis in mice

Fig. 6

Secondary transplanted primary HLA-ABC-positive cells home to CCl4-treated recipient livers. a Schema of secondary transplantation of primary HLA-ABC+/HLA-ABC– cells into C57BL/6 mice. HLA-ABC+/HLA-ABC– cells (1 × 106) or phosphate-buffered saline (PBS) were infused into the mice that had intraperitoneally received CCl4 (0.5 ml/kg) or olive oil only twice a week (red arrows). b In vivo monitoring of DiR-labeled HLA-ABC-positive (HLA +) and HLA-negative (HLA –) cells in CCl4-treated mice 24 hours (24h) after the infusion. c, d Distribution of transplanted HLA+ and HLA– cells in the secondary recipient livers. Immunohistochemistry with anti-human HLA-ABC (HLA-ABC), anti-hepatocyte paraffin 1 (Hep Par1), or anti-human albumin (hALB) antibody. Representative images. c Counterstaining with hematoxylin. The human HLA-ABC, hepatocyte paraffin 1, or human albumin-positive area. d Immunopositive area shown as the ratio to the total area. e ELISA of human albumin (hALB) in the recipient serum. c–e n = 5 for all groups. ***P <0.005. ns no significance. Graph bars show the mean ± SD. Control, olive oil-injected group; CCl4, CCl4-treated group; CCl4 + HLA+, HLA+ cell-transplanted CCl4-treated group; CCl4 + HLA–, HLA– cell-transplanted CCl4-treated group. Ab antibody, CCl 4 carbon tetrachloride, HepPar1 human hepatocyte specific HepParaffin 1 antigen, HLA human leukocyte antigen

Back to article page